AIDS TREATMENT NEWS - August 23, 2004

An August 4 New York Times article describes a new approach to clinical trials. The idea, (sometimes called "experimental medicine") is to use modern imaging, genetic, and other technology early, starting with the first patient who ever takes an experimental drug, to get solid indications of whether or not it is working. Researchers and companies make sure the drug is getting to where it is needed in the body, that it has the biochemical effects intended, and that the dose is appropriate -- eliminating losers early and focusing attention and resources on more promising drug candidates. The traditional approach uses the first human trials to pick the largest dose most patients can tolerate (which may be more than needed for medical efficacy, but is likely to become a standard dose for further research and for approval), and only then runs other trials to start testing whether the drug does anybody any good.

Comment

AIDS is barely mentioned in the article -- perhaps because it is no longer in the forefront of clinical-trial design. In AIDS and other diseases the biggest block to finding new treatments seems to be the gap between where academic research stops and where drug development begins. Many good ideas get published in journals, but usually the researchers who developed them do not do human testing, and no one does the next, relatively inexpensive steps to show which ideas have solid potential for practical development now. And usually only one company has the legal rights to a compound, so if anyone else has a good idea for using it, they (and the public as well) are often out of luck. Or nobody has exclusive rights, so no company gets involved. Clearly the current system works very poorly in turning scientific advances into new kinds of treatment, and fundamental rethinking is needed.

References

Andrew Pollack. "In drug research, the guinea pigs of choice are, well, human." The New York Times, August 4, 2004. Note: to find the article online you can search for "Garabadian" the name of a patient in a cancer trial, on http://www.nytimes.com -- however the Times requires payment for online articles older than one week.

040823
ATN040805

Copyright © 2004 - by John S. James. See "Permission to Copy" at: http://www.aidsnews.org/canhelp. How to help AIDS Treatment News: http://www.aidsnews.org/canhelp.

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.